QCG
HRTX icon

Quadrant Capital Group’s Heron Therapeutics HRTX Stock Holding History

Quadrant Capital Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-521
Closed -$2K – 2781
2022
Q3 		$2K Buy
+521
New +$2.04K ﹤0.01% 2380
2022
Q1 		– Sell
-52
Closed – – 2576
2021
Q4 		$0 Buy
+52
New +$531 ﹤0.01% 2589
2021
Q3 		– Sell
-33
Closed -$1K – 2558
2021
Q2 		$1K Buy
+33
New +$525 ﹤0.01% 2278

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Quadrant Capital Group's HRTX Position: Q4 2022 in Review

Quadrant Capital Group sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 521 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in HRTX in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2022. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Quadrant Capital Group reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 521 Heron Therapeutics shares in Q4 2022, an estimated $2K.
  • Quadrant Capital Group first reported a position in Heron Therapeutics in Q2 2021 and held it in 3 quarters.
  • Quadrant Capital Group's Heron Therapeutics position peaked at $2K in Q3 2022.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.